NEW YORK and LONDON, April 09, 2020 -- Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for.

UK biotech Tiziana Life Sciences Plc said Wednesday its TZLS-501 treatment could be used for patients with the coronavirus that causes COVID-19 and are at risk of respiratory failure. The company is accelerating development of the treatment with Novimmune SA, a Swiss biotech company. "Tests have already shown that the treatment rapidly depletes circulating levels of IL-6 in the blood," the company said in a statement. "An excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness." Shares were up more than 300% premarket. The stocks of many small biotechs and medical device companies that have made announcements relating to the virus have rallied hard as the illness has spread around the world, even though experts caution it will take a long time to develop treatments.

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, April 27, 2020 -- Tiziana Life Sciences plc.

Nasdaq and AIM listed Tiziana Life Sciences plc (Nasdaq: TLSA) (AIM: TILS) has today announced that its TZLS-501 treatment could be a potential treatment for patients infected with coronavirus (COVID-19) who are at risk of respiratory failure.

NEW YORK and LONDON , March 11, 2020 /CNW/ -- Tiziana Life Sciences plc (TLSA) (TILS.L) (the "Company" or "Tiziana"), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announced the pricing of its underwritten follow-on public offering (the "Offering") of American Depositary Shares ("ADSs") on the NASDAQ Global Market. Tiziana will issue 3,333,333 ADSs (representing 16,666,665 new ordinary shares of nominal value £0.03 each in the capital of the Company ("Ordinary Shares")) at a price to the public of $3.00 per ADS raising gross proceeds of approximately $10 million (before deducting underwriting discount, commissions and offering expenses).

Should investors buy Disney (DIS) stock for 2020 on streaming TV success against Netflix?

We found three blue-chip technology stocks, with the help of our Zacks Stock Screener, that investors might want to buy for 2020...

Tiziana Life Sciences plc (Nasdaq: TLSA) (AIM: TILS) (the "Company" or "Tiziana"), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces the closing of its underwritten follow-on public offering (the "Offering") of American Depositary Shares ("ADSs") on the NASDAQ Global Market. Tiziana issued 3,333,333 ADSs (representing 16,666,665 new ordinary shares of nominal value £0.03 each in the capital of the Company ("Ordinary Shares")) at a price to the public of $3.00 per ADS raising gross proceeds of approximately $10 million (before deducting underwriting discount, commissions and offering expenses). Each ADS offered represents five (5) Ordinary Shares. In addition, Tiziana has granted the underwriters a 45-day option to purchase up to an additional 499,999 ADSs on the same terms and conditions (the "Option"). All ADSs sold in the Offering were offered by the Company. The number of Ordinary Shares represented by ADSs comprised in the Offering (including by way of the exercise of the Option) were within existing shareholder authorities.

Companies In The News Are: TLSA, VIR, HEAR, CDMO

NEW YORK and LONDON, May 11, 2020 -- Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Dactinomycin), from Rasna Therapeutics, Inc. ("Rasna") to expand its pipeline for a consideration of an initial $120,000 upfront payment and milestone payments of up to an additional aggregate $630,000.

Billionaire Elon Musk said Tesla Inc.’s (TSLA) stock is too expensive, sending the electric carmaker’s shares down as much as 13% on Friday.“Tesla stock price is too high,” Tesla’s CEO Musk said in a Twitter post.Shares dropped 10.3% to close at $701.32 in U.S. trading on Friday. Even after the plunge, the stock is up about 63% this year. The Wall Street Journal reported that Musk responded in an email that he wasn’t joking and that his tweets weren’t vetted before he posted them. This year’s stock advance still means that Musk will be able to meet the market cap performance target he needs to receive stock options that would generate over $700 million.The outspoken billionaire, who has 33.5 million Twitter followers, also reiterated his harsh criticism regarding U.S. stay-at-home orders which are affecting Tesla’s production levels as one of its main factories in Fremont, California remains shut.“Now give people back their FREEDOM,” Musk wrote in a Twitter post on Friday. “I am selling almost all physical possessions. Will own no house.”The comments come after Musk on Wednesday told investors that the coronavirus-related regulations are a “key risk” to the business and said lockdown orders are “fascist”. Ben Kallo, analyst at Robert W. Baird, who has a Hold rating on the stock sees “significant uncertainty over the next 2 to 3 quarters” when it comes to the prospect of returning to prior production levels.“We can only guess at motivations behind his sequence of tweets,” Kallo said in a note to clients.Like Kallo, the consensus of Wall Street analysts has a Hold rating on the stock based on 11 Sells, 10 Holds and 6 Buys. The $609.90 average price target forecasts shares will decline 13% in the next 12 months. (See Tesla’s stock analysis on TipRanks)Related News: Amazon Dips 8% on $4 Billion Virus Costs Amid Prospect For 2Q Loss Apple Exceeds Expectations With FQ2 Earnings Beat Boeing Raises $25 Billion in Bond Sale, No Longer Needs Government Aid; Shares Slip

Companies In The News Are:

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, May 14, 2020 -- Tiziana Life Sciences plc (NASDAQ:.

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

Tiziana Life Sciences plc (NASDAQ: TLSA, AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announces that it intends to demerge its StemPrintER and SPARE (together "StemPrintER") genomics-based personalized medicine businesses into a separate company and effect a capital reduction to facilitate the spin-out and listing of StemPrintER as an independent entity. Allow Shareholders to benefit from both Tiziana’s rapidly developing drug portfolio and the standalone value of StemPrintER as it progresses through its own development milestones and the path to commercialization and allow shareholders to receive the maximum potential value from StemPrintER as a standalone entity.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, May 14, 2020 -- Tiziana Life Sciences plc (Nasdaq:.